Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Annovis Bio, Inc.

ANVS

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Last trade $0.7474
Day change -$0.0027 (-0.35%)
Day range $0.705 – $0.824
Volume 1,744,158
Market cap $32M

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$32.27M
Price / earnings
—
Price / book
-2.44×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.5×

Profitability

Earnings per share
-$1.20
Return on assets
-939.79%
Return on equity
390.85%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
0.88×
Quick ratio
0.88×
Cash ratio
0.45×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$55.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ANVS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.19M$2.37M$1.29M$955.15K$1.14M$1.11M$1.27M$1.74M
Research and development$15.78M$12.01M$16.72M$8.75M$6.29M$5.16M$5.01M$5M
Total operating expenses$16.97M$14.38M$18.01M$9.71M$7.43M$6.27M$6.28M$6.73M
Operating income-$16.97M-$14.38M-$18.01M-$9.71M-$7.43M-$6.27M-$6.28M-$6.73M
Interest expense-$37.9K-$1.59M$0$0$0$0$0$16.94K
Income before taxes-$9.46M-$14.82M-$17.61M-$9.83M-$7.26M-$6.22M-$5.54M-$5.86M
Income taxes$0$0$0$0$0$0$0$0
Net income-$9.46M-$14.82M-$17.61M-$9.83M-$7.26M-$6.22M-$5.54M-$5.86M
Net income attributable to common shareholders-$9.46M-$14.82M-$17.61M-$9.83M-$7.26M-$6.22M-$5.54M-$5.86M
EBITDA-$16.97M-$14.38M-$18.01M-$9.71M-$7.43M-$6.27M-$6.28M-$6.73M
Basic earnings per share-$0.22-$0.40-$0.63-$0.38-$0.37-$0.32-$0.32-$0.42
Diluted earnings per share-$0.22-$0.40-$0.63-$0.38-$0.37-$0.32-$0.32-$0.42

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

Annovis Bio (NYSE: ANVS), a Phase 3 biotech company developing buntanetap for neurodegenerative diseases, received notice from the NYSE on October 29, 2026, that it no longer meets continued listing standards. The company's 30-day average market capitalization was approximately $48.4 million (below the $50 million threshold) and it reported a stockholders' deficit of $4.3 million as of June 30, 2026. Annovis has 45 days to submit a compliance plan and 9 months to regain compliance, during which its stock will trade with a '.BC' designation indicating below-criteria status. Failure to comply could result in NYSE delisting proceedings.

GlobeNewswire Inc.

Annovis to Host Corporate Update Webinar on September 2, 2026

Annovis Bio (NYSE: ANVS) announced that its pivotal Phase 3 Alzheimer's disease trial has reached full enrollment with 850 patients, exceeding original projections. The company expects top-line data readout and regulatory submissions in 2027, with an open-label extension study beginning in October 2026. The company is also advancing its Parkinson's disease program with ongoing discussions with the FDA.

GlobeNewswire Inc.

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis Bio will present two research presentations at the CTAD conference, highlighting biomarker data for buntanetap in treating Alzheimer's and Parkinson's diseases, focusing on potential disease-modifying therapeutic approaches.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.